Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer
NCT ID: NCT07042867
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
900 participants
INTERVENTIONAL
2025-07-15
2028-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The results of this study will be used to design medical devices (software integrating risk stratification tools), which will then be evaluated as part of subsequent Clinical Investigations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway
NCT06387017
Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE
NCT05649046
Circulating Tumor Cells in Lung Cancer Screening
NCT02500693
Lung Cancer Risk Assessment and Etiology
NCT06328621
Evaluation of Lung Cancer CT Screening Performance Among Former and Current Smokers
NCT05486455
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: patients with a nodule or lung mass identified on CT scan, with no indication of an immedi
patients with a nodule or lung mass identified on CT scan, with no indication of an immediate diagnostic workup
biobanking
blood draw at each time point
low dose scan
low dose lung scan will be performed at each timepoint
Group B: cohort of patients with a nodule or lung mass identified on CT with an indication for biops
cohort of patients with a nodule or lung mass identified on CT with an indication for biopsy or excision surgery
biobanking
blood draw at each time point
low dose scan
low dose lung scan will be performed at each timepoint
Group C: Individuals with at least one risk factor for lung cancer and no prior lung imaging, but no
Individuals with at least one risk factor for lung cancer and no prior lung imaging, but not eligible for lung cancer screening according to INCa criteria.
biobanking
blood draw at each time point
low dose scan
low dose lung scan will be performed at each timepoint
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biobanking
blood draw at each time point
low dose scan
low dose lung scan will be performed at each timepoint
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
CI 1- Age \> 18 years AND CI2a- Person eligible for screening with a nodule or lung mass with no indication of reassessment by CT scan before the next round of screening, as recommended by the multidisciplinary consultation meeting OR CI2b- Person not eligible for screening with a nodule or lung mass with an indication for reassessment by CT scan without immediate diagnostic workup (PET scan, biopsy, surgery) as determined by the multidisciplinary consultation meeting.
Group B CI1- Age \> 18 years AND CI2- Indication for biopsy or surgical excision for diagnostic and therapeutic purposes proposed in a multidisciplinary consultation meeting.
Group C CI1a- Age 40 - 75 and daily smoking for at least 20 years initiated before age 15 OR CI1b- Age 50 - 75 and passive smoking for at least 20 years in a closed environment (family or workplace) OR CI1c- Age 50 - 75 and smoking 10 cig/d for 30 years or 15 cig/d for 25 years or 20 pack-years with no withdrawal period OR
CI1d- Age 50 - 75 and daily smoking for at least 10 years combined with at least one other lung cancer risk factor from among :
* Self-reported daily passive smoking for \> 10 years (smokers at home or in enclosed environments)
* Self-reported exposure to a lung carcinogen: Radon, coal smoke, soot, diesel, nickel, beryllium, arsenic, cadmium, asbestos
* 1st-degree family history of lung cancer
* Personal history of tobacco-related disease, including atheromatous cardiovascular disease, COPD or emphysema, cancer not monitored by chest imaging
* weekly use of cannabis (joints) for 10 years
All Groups:
* Have signed an informed consent form
* Affiliated with or benefiting from a social security scheme
* Male or female
Exclusion Criteria
Group C Eligible for lung cancer screening according to INCa\* criteria
* Previous cancer \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with undiagnosable PSA)
* Symptoms of lung cancer (involuntary weight loss \> 10% of usual weight in 1 year, hemoptysis)
* Known history of pulmonary nodule requiring specialized follow-up
* History of pulmonary fibrosis or pulmonary hypertension
* Active pulmonary parenchymal infection
* Severe cardiac or respiratory insufficiency (rest dyspnea)
* Performance status (WHO) 2, 3 or 4
All Groups
* patient privé de liberté
* patient sous tutelle ou curatelle
* femmes enceintes ou allaitantes
* patient dans l'incapacité d'effectuer le suivi de 30 mois
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Boulate, Professor of Medicine
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique Hopitaux De Marseille
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A02828-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.